VR Logo

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) download report


Healthcare | Biotechnology & Pharma Research

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

IPO Date: 30-Nov-2005

Pres, CEO & Exec. Director: Mr. Spiro George Rombotis

Exec. VP of Fin., CFO, COO, Sec. & Exec. Director: Mr. Paul McBarron

Listing: NASDAQ: CYCCP

Country: United States

Headquarters: Berkeley Heights, NJ

Website: https://www.cyclacel.com

Key Facts

Market cap: $12.87 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.72 Mln

Cash: $29.64 Mln

Total Debt: $0.02 Mln

Insider's Holding: 0.48%

Liquidity: Low

52 Week range: $5.17 - 10.56

Shares outstanding: 12,497,400

10 Years Aggregate:

  • CFO: $-123.59 Mln
  • EBITDA: $-130.98 Mln
  • Net Profit: $-118.78 Mln

Stock Performance

Time Period Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) S&P BSE Sensex* S&P Small-Cap 600*
YTD11.59-8.47-17.79
1 month4.48-1.72-2.72
3 months8.32-7.05-12.17
1 Year-26.940.74-15.82
3 Years21.4410.437.14
5 Years12.2211.366.20
10 Years--12.1710.33
As on 24-Jun-2022 *As on 27-Jun-2022
Year Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) S&P Small-Cap 600 S&P BSE Sensex
2021-5.6325.2721.99
202056.249.5715.75
2015-31.72-3.36-5.03